STOP THE WAR! Let’s support Ukraine Together

Mountain Crest Acquisition Corp. II (MCAD) Shareholders Approve Better Therapeutics Deal

Mountain Crest Acquisition Corp. II (MCAD) Shareholders Approve Better Therapeutics Deal

Mountain Crest Acquisition Corp. II (NASDAQ:MCAD) announced in a press release that it secured shareholder approval of its combination with biopharmaceutical firm Better Therapeutics in a special meeting held earlier today. Although the press release did not disclose redemption amounts, MCAD traded below $10 throughout its redemption deadline October 25.  However, the SPAC reached a
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.